PainReform has released details on, and the commencement of, its development plan for OcuRing-K, including an upcoming phase 2 clinical trial. 1 ...

Of the 1000 patients with dry eye symptoms surveyed, 80% stated that “they would try a science-backed eye drop that mimics ...

Iolyx Therapeutics and Laboratoires Théa (Théa), through support from its subsidiary Théa Open Innovation, have entered into ...

The panel reviews the mechanisms, efficacy, and tolerability of novel treatments, including perfluorohexyloctane (Miebo), ...

The US Patent and Trademark Office has issued a new patent (US Patent No. 12,472,263) on additional and novel formulations of ...

Belite Bio has released topline results from the global phase 3 DRAGON trial of Tinlarebant in patients with Stargardt ...

The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ cyclosporine ophthalmic emulsion 0.05%, which ...

Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...

The CEO of Dean McGee Eye Institute reflects on the program’s milestones, global partnerships, and the future of ...

Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...

Prevent Blindness has declared the first week of December as its 5th annual geographic atrophy (GA) week to educate the ...

Lid margin collarettes are common in moderate-to-severe DED, but most do not progress over time. No link was found between ...